证券代码：688759 证券简称：必贝特 公告编号：2026-001 广州必贝特医药股份有限公司 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 经公司自查，并发函问询公司实际控制人及其一致行动人，截至本公告 披露日，公司日常经营情况正常，未发生重大变化，不存在应披露而未披露的重 大信息。 公司是一家采用第五套上市标准的生物医药公司，公司仅有1款产品获批 上市，1款产品处于III期临床试验阶段，1款产品已获准开展III期临床试验，5款 产品处于I期临床试验阶段，其他产品尚处于临床前研究阶段。公司目前尚未盈 利且存在累计未弥补亏损，预期未来仍需要较大规模的持续研发投入。由于生物 医药行业以其研发周期长、资本投入大和成功不确定性高等特点而显著。新药从 早期发现到最终商业化，需经历临床前研究、临床开发、监管审批、生产及市场 推广等多重环节，其中充满诸多不确定性。 2025年1-9月，公司尚未实现销售收入，归属于母公司股东的净利润为 -10,746.99万元，较去年同期变化不大，公司经营状况总体良好，未发生重 ...

Core Viewpoint - The stock of Bibet has experienced significant volatility, with a cumulative price increase of 30% over three consecutive trading days from January 5 to January 7, 2026 [1] Group 1: Stock Performance - Bibet's stock price has deviated significantly, with a cumulative increase of 30% over three trading days [1] - The company has issued a notice regarding the abnormal fluctuations in its stock trading [1] Group 2: Company Operations - As of the date of the announcement, the company's daily operations are normal, with no significant changes reported [1] - The company has not disclosed any major information that should have been reported [1] Group 3: Financial Performance - For the period from January to September 2025, the company has not generated any sales revenue [1] - The net profit attributable to the parent company's shareholders is -107.47 million yuan, showing little change compared to the same period last year [1] - Overall, the company's operational status is considered stable, with no significant changes [1]

Group 1 - The A-share market saw a collective rise in innovative drug concept stocks on January 7, with notable gains including a 20% increase for Beibete-U and over 17% for Yinos. [1] - Other significant performers included Chengdu XianDao with a 13% rise, and Panlong Pharmaceutical reaching a 10% increase. [1] - Additional stocks such as Yangguang Nuohuo and Zhaoyan New Drug also experienced gains exceeding 9% and 7% respectively. [1] Group 2 - The table lists various stocks with their respective codes, showing percentage increases, total market capitalization, and year-to-date performance. [2] - Beibete-U (688759) had a market cap of 18.6 billion with a year-to-date increase of 42.46%. [2] - Yinos (688710) reported a market cap of 7.611 billion and a year-to-date increase of 22.29%. [2] - Chengdu XianDao (688222) had a market cap of 12.2 billion and a year-to-date increase of 29.59%. [2] - Other stocks listed include Panlong Pharmaceutical (002864) with a market cap of 3.706 billion and a year-to-date increase of 13.07%, and Yangguang Nuohuo (688621) with a market cap of 8.188 billion and a year-to-date increase of 17.63%. [2]

Group 1 - The A-share market saw a collective rise in innovative drug concept stocks, with notable gains including a 20% limit up for Beibetter-U and over 17% increase for Yinos [1] - Other significant performers included Chengdu XianDao with over 13% rise, and Panlong Pharmaceutical with a 10% limit up [1] - Additional stocks such as Sunshine Nuohuo and Zhaoyan New Drug also experienced increases of over 9% and 7% respectively [1] Group 2 - The table lists various stocks with their respective price changes, total market capitalization, and year-to-date performance, highlighting Beibetter-U's market cap at 18.6 billion and a year-to-date increase of 42.46% [2] - Yinos has a market cap of 7.611 billion with a year-to-date increase of 22.29%, while Chengdu XianDao's market cap is 12.2 billion with a 29.59% increase [2] - Other notable stocks include Panlong Pharmaceutical with a market cap of 3.706 billion and a 13.07% year-to-date increase, and Sunshine Nuohuo with a market cap of 8.188 billion and a 17.63% increase [2]

Group 1 - The chemical pharmaceutical sector increased by 3.63% on January 5, with Frontier Biotech leading the gains [1] - The Shanghai Composite Index closed at 4023.42, up 1.38%, while the Shenzhen Component Index closed at 13828.63, up 2.24% [1] - Notable stock performances included Frontier Biotech with a closing price of 21.20, up 17.45%, and Beilu Pharmaceutical at 66.8, up 13.22% [1] Group 2 - The chemical pharmaceutical sector saw a net inflow of 716 million yuan from institutional investors, while retail investors contributed a net inflow of 131 million yuan [2] - Major stocks with significant net inflows included Heng Rui Pharmaceutical with 17.4 million yuan and ST Renfu with 9.15 million yuan [3] - Conversely, stocks like ST Jinfeng and Kangzhiyue experienced net outflows of 6.90 million yuan and 11.61 million yuan respectively [2][3]

截至12月10日，必贝特股东户数1.94万，较上期减少18.91%；人均流通股2390股，较上期增加23.33%。 2025年1月-9月，必贝特实现营业收入0.00元；归母净利润-1.07亿元。 责任编辑：小浪快报 融资方面，必贝特当日融资买入766.89万元。当前融资余额8085.23万元，占流通市值的5.94%。 融券方面，必贝特12月19日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00元； 融券余量0.00股，融券余额0.00元。 资料显示，广州必贝特医药股份有限公司位于广东省广州市高新技术产业开发区科学城崖鹰石路25号 A-3栋第七层、第八层，成立日期2012年1月19日，上市日期2025年10月28日，公司主营业务涉及创新 药自主研发。 12月19日，必贝特涨1.31%，成交额1.12亿元。两融数据显示，当日必贝特获融资买入额766.89万元， 融资偿还991.06万元，融资净买入-224.17万元。截至12月19日，必贝特融资融券余额合计8085.23万 元。 ...

证券日报网讯12月19日，必贝特在互动平台回答投资者提问时表示，截至2025年12月10日，公司股东人 数为19434户。 ...

Group 1 - The core viewpoint of the articles highlights the fundraising activities of companies listed on the STAR Market, with a total of 17 companies raising 35.089 billion yuan this year, averaging 2.064 billion yuan per company [1][2] - Among the companies, Moer Technology raised the most at 8 billion yuan, primarily for cash management and the development of AI training chips and graphics chips [1] - Other notable fundraisers include Xian Yicai with 4.636 billion yuan for its silicon industry base project, and Muxi Co., Ltd. with 4.197 billion yuan [1] Group 2 - The average initial offering price for STAR Market stocks this year is 36.56 yuan, with four companies priced above 50 yuan, and two exceeding 100 yuan, the highest being Moer Technology at 114.28 yuan [2] - The issued price-earnings ratio ranges from 6.14 to 519.12, with an average of 83.91 and a median of 42.64, where C Bai Ao has the highest ratio at 519.12 [2] - Geographically, the majority of the issued companies are concentrated in Beijing, Hubei, and Guangdong, with fundraising amounts led by Beijing at 14.692 billion yuan [2]

证券日报网讯12月9日，必贝特在互动平台回答投资者提问时表示，目前，公司在研产品管线中，暂无 专门针对流感病毒的特效药物。 ...

格隆汇12月9日丨必贝特(688759.SH)在互动平台表示，目前，我司在研产品管线中，暂无专门针对流感 病毒的特效药物。 ...